Koen Kas, PhD
InBioVeritas, Antwerp, Belgium
Prof. Dr. Koen Kas is a healthcare game-changer who has developed unique views on what’s happening in the global health community. He recently published his vision in a book (“Sick no more”, currently in Dutch only), describing a predictive and preventive healthcare which is 4 DiMEnSiOnAL: Digital, Mobile, Engaging, Social, iOmic-based, quantified, Attractive & Local.
He is founding CEO of InBioVeritas, trendspotting developments at the crossroads of biology, medicine, ICT, engineering/electronics and behavioural sciences. He uses these insights in different ideation and advisory roles facilitating innovative disruptions in healthcare and creating novel digital health startups.
He serves on the Scientific Advisory Board of a number of large tech & life sciences companies & investors. Before, he spent 14 years in Executive positions at 4 leading biotech companies. As CSO Oncology of Thrombogenics he prepared the spin-out of the oncology franchise into a new venture. Before that, Koen was founding CEO & CSO of Pronota, a company committed to better diagnosis and personalized medicine. He also developed digital next generation –omics tools. He was, prior to that Director drug discovery at Galapagos. Previously, he set up and directed the Cancer drug discovery program at Tibotec (now Johnson & Johnson).
Koen is professor Molecular Oncology at Ghent University, Belgium, and chairs the scientific committee of the European Cancer Prevention Organisation.
He received his PhD degree in Biomedical Sciences from the University of Antwerp where he also obtained a degree in Business Administration. In 1999 he was appointed professor at the University of Leuven, Belgium and lecturer at Harvard University, Boston, USA. He is author of over 60 publications in international journals and he authored over 20 patents and patent applications. He is a member of different scientific societies and received prestigious awards from NATO and the Collen Research Foundation and from the Royal Belgian Academy of Sciences and the Belgian Royal Academy of Medicine.
Terms of Appointment: April, 2015 - March, 2018; April, 2018 - March, 2020